UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 96 filers reported holding UNIQURE NV in Q4 2018. The put-call ratio across all filers is 0.07 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $5,208 | +48.8% | 258,571 | +67.5% | 0.02% | +46.2% |
Q4 2022 | $3,500 | -99.8% | 154,409 | +268.8% | 0.01% | +225.0% |
Q1 2021 | $1,411,000 | -6.7% | 41,871 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,513,000 | -1.9% | 41,871 | 0.0% | 0.00% | -20.0% |
Q3 2020 | $1,542,000 | -62.1% | 41,871 | -53.6% | 0.01% | -64.3% |
Q2 2020 | $4,067,000 | -73.1% | 90,254 | -71.7% | 0.01% | -79.1% |
Q1 2020 | $15,129,000 | -48.9% | 318,833 | -22.8% | 0.07% | -32.3% |
Q4 2019 | $29,582,000 | +84.8% | 412,815 | +1.5% | 0.10% | +83.3% |
Q3 2019 | $16,010,000 | -64.9% | 406,747 | -30.4% | 0.05% | -63.5% |
Q2 2019 | $45,666,000 | +18.2% | 584,329 | -9.8% | 0.15% | +14.7% |
Q1 2019 | $38,631,000 | +786.2% | 647,626 | +328.1% | 0.13% | +706.2% |
Q4 2018 | $4,359,000 | -18.8% | 151,271 | +2.5% | 0.02% | +6.7% |
Q3 2018 | $5,371,000 | +193.2% | 147,589 | +64.7% | 0.02% | +150.0% |
Q3 2015 | $1,832,000 | -68.8% | 89,585 | -58.8% | 0.01% | -60.0% |
Q2 2015 | $5,876,000 | – | 217,656 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |